-
2024-09-23
Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East Asia
Nuance Pharma announced that it has agreed with Altamira Medica Ltd. to extend the territory covered by the exclusive license and distribution agreement for Bentrio® nasal spray by several countries across South East and East Asia.
-
2024-09-11
Nuance Pharma completes recruitment for ENHANCE-CHINA, the phase 3 clinical trial of ensifentrine for the maintenance treatment of COPD
Nuance Pharma announced it has completed the recruitment of patients for the ENHANCE-CHINA study, after planned number of patients have been successfully enrolled.
-
2024-08-14
PharmaBoardroom Interview with Nuance Pharma founder & CEO Mark Lotter
From a demographic and disease profile perspective, Asia-Pacific shares more similarities with China than with Western markets. This alignment makes expanding into Asia-Pacific a logical step.
-
2024-06-27
US FDA New Drug Application Approval of Ohtuvayre™ (ensifentrine) for the Maintenance Treatment of COPD
Nuance Pharma's global partner Verona Pharma plc (Nasdaq: VRNA), announces the US Food and Drug Administration ("FDA") approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patie
-
2023-06-28
Nuance Pharma's Partner Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD
Nuance Pharma announces its partner, Verona Pharma plc (Nasdaq: VRNA), has submitted a New Drug Application ("NDA") to the US Food and Drug Administration ("FDA") for approval of ensifentrine fo
-
2023-05-26
Nuance Pharma's Partner Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
Altamira Therapeutics Ltd. (Nasdaq: CYTO) announced positive and statistically significant top-line results from the randomized controlled NASAR clinical trial evaluating its Bentrio nasal spray in patients with seas
-
2023-04-25
优锐医药First-in-Class慢阻肺管线中国III期顺利启动，加速推进呼吸特药精耕
动脉网获悉，专注呼吸类创新药的生物医药公司：优锐医药，已经于2023年4月6日完成Ensifentrine ENHANCE - CHINAIII期临床试验的首例患者给药，适用于中国大陆区域慢性阻塞性肺疾病(COPD)疾病的维持治疗。
-
2023-04-06
Ensifentrine Completes Dosing of First Patient in ENHANCE - CHINA Phase III Trial for COPD
Nuance Pharma announces dosing of first patient in the ENHANCE - China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease ("COPD") of its novel
Contact PR
